Published in Pharmacogenomics J on April 12, 2016
The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther (2007) 4.33
Carrier screening in individuals of Ashkenazi Jewish descent. Genet Med (2008) 4.13
The genome-wide structure of the Jewish people. Nature (2010) 3.37
Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med (2004) 2.83
A genetic profile of contemporary Jewish populations. Nat Rev Genet (2001) 2.51
Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations. Am J Hum Genet (2008) 1.99
Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. Clin Pharmacol Ther (2014) 1.84
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors. Clin Pharmacol Ther (2015) 1.49
Cytochrome P450 2D6. Pharmacogenet Genomics (2009) 1.22
A substantial prehistoric European ancestry amongst Ashkenazi maternal lineages. Nat Commun (2013) 1.09
The population genetics of the Jewish people. Hum Genet (2012) 1.00
Multi-ethnic distribution of clinically relevant CYP2C genotypes and haplotypes. Pharmacogenomics J (2012) 0.97
CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population. Pharmacogenomics (2007) 0.95
CYP2D6 and the severity of suicide attempts. Pharmacogenomics (2011) 0.86
Interethnic variability of CYP2D6 alleles and of predicted and measured metabolic phenotypes across world populations. Expert Opin Drug Metab Toxicol (2014) 0.86
Identification of CYP2C19*4B: pharmacogenetic implications for drug metabolism including clopidogrel responsiveness. Pharmacogenomics J (2011) 0.84
Ethnic differences in CYP2C9*2 (Arg144Cys) and CYP2C9*3 (Ile359Leu) genotypes in Japanese and Israeli populations. Life Sci (2005) 0.83
Extended haplotype association study in Crohn's disease identifies a novel, Ashkenazi Jewish-specific missense mutation in the NF-κB pathway gene, HEATR3. Genes Immun (2013) 0.83
A combined high CYP2D6-CYP2C19 metabolic capacity is associated with the severity of suicide attempt as measured by objective circumstances. Pharmacogenomics J (2014) 0.83
Multi-ethnic cytochrome-P450 copy number profiling: novel pharmacogenetic alleles and mechanism of copy number variation formation. Pharmacogenomics J (2012) 0.82
Distribution of CYP2C9 and VKORC1 risk alleles for warfarin sensitivity and resistance in the Israeli population. Curr Drug Saf (2010) 0.82
High risk of lifetime history of suicide attempts among CYP2D6 ultrarapid metabolizers with eating disorders. Mol Psychiatry (2011) 0.79
CYP2D6 genotype and dextromethorphan hydroxylation phenotype in an Ecuadorian population. Eur J Clin Pharmacol (2011) 0.79
CYP2D6 ultrarapid metabolism and early dropout from fluoxetine or amitriptyline monotherapy treatment in major depressive patients. Mol Psychiatry (2012) 0.79
Polymorphisms of CYP2C19 and CYP2D6 in Israeli ethnic groups. Am J Pharmacogenomics (2004) 0.78
Breast cancer incidence rates among orthodox Jewish women. J Immigr Minor Health (2014) 0.77
Development of a PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential use. Biotechniques (2005) 0.77
Pharmacogenetics in Jewish populations. Drug Metabol Drug Interact (2014) 0.75
High-throughput analysis of informative CYP2D6 compound haplotypes. Genomics (2003) 0.75
Population pharmacogenetics of Ibero-Latinoamerican populations (MESTIFAR 2014). Pharmacogenomics (2015) 0.75